MEET 2015 - Nice

Carotid Occlusive Disease - Are we ready for the next breakthrough

STATE OF THE ART: PROMISING NEXT STEPS

K. MathiasKlinische und Interventionelle AngiologieAK St. Georg Hamburg



Nothing to disclose in regard to this presentation

Different Pathologies

Atherosclerosis
>90% of the pts.
Dissection
Trauma
Inflammation




What we want to achieve ...

Prevention of stroke: - asymptomatic ICA stenosis - TIA Treatment: - asymptomatic ICA stenosis - TIA BMT stenosis <80%</p> CAS stenosis >80% CEA stenosis > 80%

What we want to achieve ...


Treatment of stroke: - acute phase - thrombectomy - thrombolysis - delayed phase - CEA or CAS - major stroke - conservative tx

Acute Stroke - Thrombectomy ICA



B.G. f-66 Aphasic and hemiplegic for 4 hrs

TIA - CAS immediately after Loading



P.N. m-71 TIA - Aphasic for 10min - 300 mg aspirin and 600 mg clopidogrel - CAS 7 hrs after symptom onset

TIA - CAS immediately after Loading

AK m-74 yrs 6 years after CEA right carotid minor stroke left hemisphere 2x TIA right hemisphere pulsating ear noise left ICA occluded right ECA occluded right ICA several stenoses




Technique

CAS - Always with Cerebral Protection

When filter, when proximal balloon protection?

No high level evidence, but data from TCD and DW-MRI

CAS - Always with Cerebral Protection



*own results: AJNR, 2001; 22-:1251-1259

CAS - Always with Cerebral Protection

Filter, when
asymptomatic patient
little plaque burden
no ICA kinks
no additional distal disease

Filter Protection



a selection of filters they are different be familiar with their behaviour



Disadvantages of Filter Protection

- crossing the lesion unprotected - pore size >100 μ
- not always complete apposition
 retrieval may be difficult





... but flow preserved during the intervention


Proximal Balloon Protection

Flow Reversal NPS Gore

MO.MA









ROADSTER trial with the Silk Road Procedure; 2013

Mesh Covered Stent Technology





plaque prolaps through stent meshes

fine meshwork prevents plaque prolaps

Hybrid Stent should prevent
plaque prolaps
late embolic events

Prof. Dr. Klaus Mathias, TCT 2013


Stents - What is new?

Hybrid Stents

3 products trials still running

CGuard Gore Terumo


CGuard[™] Carotid Embolic Protection with MicroNet[™] by InspireMD



mesh size 150-190 µ



Gore Hybrid Stent



Open question:

Does more scaffolding stimulate intimal proliferation and influence the long term results?

Clinical Outcome

New Trials?

No major PRT running in symptomatic patients

SPACE-2 stopped due to slow enrolement - MAE <2%

CREST-2 planned


SEPTEMBER 2013

CREST-2: Guiding Treatments for Asymptomatic Carotid Disease Examining stenting and endarterectomy in the context of intensive medical management. By Braiesh K. Lal, MD; James F. Meschia, MD; and Thomas G. Brott, MD

New Trials?

Trial name	Groups	Reference
SPACE-2	asymptomatic stenosis A: CEA+best medical vs. best medical B: CAS+ best medical vs. best medical	Reiff et al., 2014
ACST-2	asymptomatic stenosis CAS vs. CEA	Halliday et al., 2013
ACTI	asymptomatic stenosis CAS vs. CEA 3:1	
CREST-2	asymptomatic stenosis A: CEA+best medical vs. best medical B: CAS+ best medical vs. best medical	

CAS Operator Experience in Medicare Beneficiaries



What do the guidelines tell us?





 clear evidence for symptomatic stenoses ≥70%: CEA

• CAS alternative to CEA in patients with high surgical risk

• CAS alternative to CEA in centers with high volume and complication rate <6%

• strict selection in asymptomatic patients: stenosis \geq 60%, complication rate of both methods \leq 3%

- symptomatic stenosis ≥70%: CEA
- CAS equal alternative for CEA
- complication rate $\leq 6\%$ for both methods
- in elderly patients (>75 years) CEA preferred to CAS
- unfavorable neck anatomy: CAS preferred to CEA
- strict selection in asymptomatic patients

